These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 33901324

  • 21. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Schoen MW, Woelich SK, Braun JT, Reddy DV, Fesler MJ, Petruska PJ, Freter CE, Lionberger JM.
    Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
    [Abstract] [Full Text] [Related]

  • 22. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
    Li GH, Chen RA, Ji YR, Qin WW, Chen Y, Wang WQ, Liu C, Zhou NC, Liu L.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
    [Abstract] [Full Text] [Related]

  • 23. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
    Cao L, Jiang ZQ, Liu WJ, Sun Q, Zhu Y, Li JY, Qian SX, Hong M.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
    [Abstract] [Full Text] [Related]

  • 24. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L, Myint H, Singer JW, Estey E, Pagel JM.
    Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
    [Abstract] [Full Text] [Related]

  • 25. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
    Choi M, Song J, Bui CN, Ma E, Chai X, Yin L, Betts KA, Kapustyan T, Montez M, LeBlanc TW.
    J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
    Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.
    Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.
    Palmieri R, Buckley SA, Othus M, Halpern AB, Percival MM, Scott BL, Hendrie PC, Becker PS, Oehler VG, Estey EH, Walter RB.
    Leuk Lymphoma; 2020 Jul; 61(7):1728-1731. PubMed ID: 32077361
    [No Abstract] [Full Text] [Related]

  • 31. Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
    Mayer K, Hahn-Ast C, Schwab K, Schmidt-Wolf IGH, Brossart P, Glasmacher A, von Lilienfeld-Toal M.
    Eur J Haematol; 2020 Jun; 104(6):538-545. PubMed ID: 32049382
    [Abstract] [Full Text] [Related]

  • 32. The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.
    Molica M, Breccia M, Capria S, Trisolini S, Foa R, Jabbour E, Kadia TM.
    Leuk Lymphoma; 2020 Mar; 61(3):536-545. PubMed ID: 31752577
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL.
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Choi EJ, Lee JH, Park HS, Lee JH, Seol M, Lee YS, Kang YA, Jeon M, Woo JM, Lee KH.
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
    [Abstract] [Full Text] [Related]

  • 39. Decitabine Compared With Conventional Regimens in Older Patients With Acute Myeloid Leukemia: A Meta-Analysis.
    Bian MR, Yang HS, Lin GQ, Wan Y, Wang L, Si YJ, Zhang XX, Wang M, Zhou H, Zhao GS, Zhang YM.
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):e636-e648. PubMed ID: 31645307
    [Abstract] [Full Text] [Related]

  • 40. Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
    Stone A, Zukerman T, Flaishon L, Yakar RB, Rowe JM.
    Leuk Res; 2019 Jul; 82():36-42. PubMed ID: 31152922
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.